Skip to main content

Arzu Umar's Proposal
Identification of functional pathways associated with clinical tamoxifen-resistance in breast cancer by advanced mass spectrometry


EMSL Project ID
14092

Abstract

Treatment of breast carcinomas with endocrine therapy is beneficial to patients until the point of therapy resistance is reached. In 50% of the cases resistance to endocrine therapy is intrinsic, while the other half shows partial or complete response. Specific gene profiles of tumors can predict beforehand whether such resistance will occur. It is thus likely that this directly reflects changes in the proteomic profile of the tumors as well. It is widely hypothesized that local changes in protein expressions may eventually lead to differences in protein compositions of body fluids as well, such as serum or plasma. Therefore, body fluids may be a useful source to search for biomarkers.

Project Details

Project type
Exploratory Research
Start Date
2005-04-15
End Date
2006-02-23
Status
Closed

Team

Principal Investigator

Arzu Umar
Institution
Erasmus University Medical Center, Rotterdam

Related Publications

A. Umar, H. Kang, A.M. Timmermans, M.P. Look, M.E. Meijer-van Gelder, N. Jaitly, M. Den Bakker, J.W.M. Martens, T.M. Luider, J.A. Foekens, L. Pasa-Tolić. Identification of a putative protein-profile associating with tamoxifen therapy-resistance in breast cancer. Molecular & Cellular Proteomics, 8 (6):1278-1294 (2009)
nLC-FTICR in BC
proteomics technical brief